Skip to main content
PMC home page
The Ulster Medical Journal logoLink to The Ulster Medical Journal
. 1996 May;65(1):55–57.

Antineutrophil cytoplasmic antibodies in myelodysplasia.

D R Hull 1, S A McMillan 1, I M Rea 1, N Boyd 1, M F McMullin 1
PMCID: PMC2448746  PMID: 8686102

Abstract

Antibodies to neutrophil cytoplasmic antigens (ANCA) are good serological markers for patients with mainly vasculitic conditions. Two main types of ANCAs have been detected, the first termed cytoplasmic antineutrophil cytoplasmic antibody (cANCA) are mainly associated with patients with Wegener's granulomatosis, the other termed perinuclear antineutrophil cytoplasmic antibody (pANCA) are mainly associated with patients with renal vasculitis, rheumatic and collagen disorders. These antibodies are against various constituents of neutrophil granules. In patients with myelodysplasia, defects in normal granulocyte development are seen. We report a series of twelve patients with myelodysplasia of whom at least four showed a low titre and one a high titre of pANCA. Two of these patients also had demonstrable activity against myeloperoxidase (MPO). None of these patients had any evidence of systemic or cutaneous vasculitis or of any autoimmune disorder. There was no pANCA positivity in an age matched control group.

Full text

PDF
56

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189–199. [PubMed] [Google Scholar]
  2. Boogaerts M. A., Nelissen V., Roelant C., Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol. 1983 Oct;55(2):217–227. doi: 10.1111/j.1365-2141.1983.tb01241.x. [DOI] [PubMed] [Google Scholar]
  3. Goldschmeding R., Tervaert J. W., Dolman K. M., von dem Borne A. E., Kallenberg C. G. ANCA: a class of vasculitis-associated autoantibodies against myeloid granule proteins: clinical and laboratory aspects and possible pathogenetic implications. Adv Exp Med Biol. 1991;297:129–139. doi: 10.1007/978-1-4899-3629-5_11. [DOI] [PubMed] [Google Scholar]
  4. Green A. R., Shuttleworth D., Bowen D. T., Bentley D. P. Cutaneous vasculitis in patients with myelodysplasia. Br J Haematol. 1990 Mar;74(3):364–365. doi: 10.1111/j.1365-2141.1990.tb02597.x. [DOI] [PubMed] [Google Scholar]
  5. Gross W. L., Schmitt W. H., Csernok E. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol. 1993 Jan;91(1):1–12. doi: 10.1111/j.1365-2249.1993.tb03345.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hagen E. C., Ballieux B. E., van Es L. A., Daha M. R., van der Woude F. J. Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood. 1993 Apr 15;81(8):1996–2002. [PubMed] [Google Scholar]
  7. Milner G. R., Testa N. G., Geary C. G., Dexter T. M., Muldal S., MacIver J. E., Lajtha L. G. Bone marrow culture studies in refractory cytopenia and 'smouldering leukaemia'. Br J Haematol. 1977 Feb;35(2):251–261. doi: 10.1111/j.1365-2141.1977.tb00582.x. [DOI] [PubMed] [Google Scholar]
  8. Ruutu P. Granulocyte function in myelodysplastic syndromes. Scand J Haematol Suppl. 1986;45:66–70. doi: 10.1111/j.1600-0609.1986.tb00846.x. [DOI] [PubMed] [Google Scholar]
  9. Warren A. J., Hegde U. M., Nathwani A., Reilly I. A. Systemic vasculitis and myelodysplasia. Br J Haematol. 1990 Aug;75(4):627–629. doi: 10.1111/j.1365-2141.1990.tb07818.x. [DOI] [PubMed] [Google Scholar]
  10. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl. 1989;6:12–13. [PubMed] [Google Scholar]

Articles from The Ulster Medical Journal are provided here courtesy of Ulster Medical Society

RESOURCES